<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253786</url>
  </required_header>
  <id_info>
    <org_study_id>DNETT-Japan</org_study_id>
    <nct_id>NCT00253786</nct_id>
  </id_info>
  <brief_title>Study for the Effectiveness of Intensive Therapy Aiming at a Remission of Diabetic Nephropathy</brief_title>
  <official_title>Study for the Effectiveness of Intensive Therapy for Diabetic Nephropathy in Unblinded, Randomized Intergroup Comparison Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Okayama University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Okayama University</source>
  <brief_summary>
    <textblock>
      Study for the effectiveness of intensive therapy aiming at the remission of diabetic
      nephropathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study for the effectiveness of intensive therapy for diabetic nephropathy in unblinded,
      randomized intergroup comparison study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2005</start_date>
  <completion_date type="Actual">November 27, 2014</completion_date>
  <primary_completion_date type="Actual">November 27, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary protein/creatinine ratio (in the first morning urine sample) in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of retinopathy in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin/creatinine ratio in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria (24 h collection sample) in Protocol A</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of retinopathy in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin/creatinine ratio in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary protein/creatinine ratio in Protocol B</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Intensive multifactorial therapy (Protocol A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol A: serum creatinine &lt;1.2 mg/dl in male and &lt;1.0 mg/dl in female.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy (Protocol A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol A: serum creatinine &lt;1.2 mg/dl in male and &lt;1.0 mg/dl in female.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive multifactorial therapy (Protocol B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy (Protocol B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive multifactorial therapy</intervention_name>
    <description>Blood glucose control: HbA1c &lt; 5.8% Blood pressure control: SBP &lt; 125 mmHg, DBP: &lt; 75 mmHg Lipid profile: T-cho &lt; 180 mg/dl, LDL-cho &lt; 100 mg/dl, HDL-cho &gt;40 mg/dl Dietary intervention: TDEI &lt; 30 kcal/kg/day, sodium &lt; 5 g/day, protein &lt; 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, muitivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care</description>
    <arm_group_label>Intensive multifactorial therapy (Protocol A)</arm_group_label>
    <arm_group_label>Intensive multifactorial therapy (Protocol B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Blood glucose control: HbA1c &lt; 6.5% Blood pressure control: SBP &lt; 130 mmHg, DBP: &lt; 80 mmHg Lipid profile: T-cho &lt; 200 mg/dl, LDL-cho &lt; 120 mg/dl, HDL-cho &gt;40 mg/dl, Dietary intervention: TDEI &lt; 25-30 kcal/kg/day, sodium &lt; 6 g/day, protein &lt; 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)</description>
    <arm_group_label>Standard therapy (Protocol A)</arm_group_label>
    <arm_group_label>Standard therapy (Protocol B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 2 diabetes

          2. Urinary albumin-to-creatinine ratio: &gt;=300 mg/g creatinine twice in the first morning
             urine sample

          3. Serum creatinine level: =&lt;2.5 mg/dl

          4. Patients aged 20-75 years

        Exclusion Criteria:

          1. Type 1 diabetes

          2. Hereditary diabetes or secondary diabetes

          3. Non-diabetic nephropathy

          4. Familial hypercholesterolemia

          5. Secondary hypertension

          6. Unstable angina pectoris or history of myocardial infarction/stroke within 6 months
             prior to consent acquisition

          7. Malignant tumor or life threatening disease

          8. History of angioedema

          9. Patients undergoing LDL apheresis

         10. Billiary system obstruction or severe liver injury

         11. Liver dysfunction

         12. Allergy for ACE-Is, ARBs or HMG-CoA reductase inhibitors

         13. Pregnant or nursing patients

         14. Others: patients who are not suitable for this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hirofumi Makino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2005</study_first_submitted>
  <study_first_submitted_qc>November 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Okayama University</investigator_affiliation>
    <investigator_full_name>Kenichi Shikata</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

